Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 7/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31284940 | 0.79 | HRH3 (0.47) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL21401254 | 0.75 | ADRA1D (1.00) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL955967 | 0.71 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CTAAR1 | |
| SCHEMBL2105196 | 0.71 | EED (0.39) | CYP3A4 | |
| SCHEMBL1602646 | 0.69 | EED (0.42) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL2626817 | 0.69 | ADRA1D (0.63) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| Detomidine SCHEMBL2626815 | 0.69 | ADRA1D (0.58) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| Detomidine SCHEMBL29833001 | 0.69 | ADRA1D (0.58) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL2626853 | 0.69 | HRH3 (0.59) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4403574 | 0.68 | ADRA1D (0.61) | ADRA1DADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | claimed |
| WO-2024260319-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-12-26 | — | — | WO | claimed |
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024260319-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-12-26 | — | — | WO | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | ADRA1D 36/4885ADRA2A 116/4885ADRA2B 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.